GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B6760 GR 231118Summary: neuropeptide Y (NPY) Y1 receptor antagonist -
B6809 MEN 10376Summary: NK2 receptor antagonist -
B6813 [bAla8]-Neurokinin A(4-10)Summary: NK2 receptor agonist -
B6838 N6-CyclopentyladenosineSummary: adenosine A1 receptor agonist -
B6871 Seglitide acetateSummary: sst2 and sst5 somatostatin receptors agonist -
B6872 IRL-2500Target: ETA Receptors|ETB ReceptorsSummary: endothelin receptor antagonist -
B6886 AlytesinSummary: Amphibian bombesin-like peptide -
B6888 N-Formyl-Met-Leu-PheSummary: formyl peptide receptor 1 (FPR1) agonist -
B6889 G-Protein antagonist peptideSummary: Inhibits G protein activation by GPCRs -
B6890 U 466193 CitationSummary: selective agonist of prostaglandin H2 (PGH2)/thromboxane A2 (TxA2) (TP) receptor

